Frenemies: New Collaboration Models
Once-fierce competitors are now collaborating on vaccine discovery, while also working to keep their exclusive pipelines primed. Is this a model that will outlast the crisis? We’ll take a deep dive into pharma R&D, for coronavirus and beyond.
Hal Barron, Chief Scientific Officer and President, R&D, GSK
John Reed, Executive Vice President, Global Head of R&D, Sanofi
Interviewer: Meg Tirrell, Senior Health and Science Reporter, CNBC
What’s Next for Biotech and Health-Care Start-ups?
Once-promising venture-backed start-ups are folding, while some companies with possible treatments have enjoyed a moment in the sun. But where will values be once the crisis is over? Which companies are set to gain — or lose — the most?
Mike Pellini, Managing Partner, Section 32
Julie Sunderland, Co-founder and Managing Partner, Biomatics Capital
Interviewer: Chrissy Farr, Health and Technology Reporter, CNBC.com
Data Is the New Rx
Whether it is tracking the coronavirus outbreak or finding candidates for clinical trials, pinpointing marketing efforts or making health care more cost efficient, data is transforming the industry. We’ll examine the ways that transformation is happening now and how it will accelerate in the future.
Arif Nathoo, Co-Founder and CEO, Komodo Health
Peter Lee, Corporate Vice President, Microsoft Research & Incubation
Interviewer: Bertha Coombs, Reporter, CNBC
High Value Care Post-COVID | Sponsored & Programmed by HSS
Hospitals and health systems have undergone rapid changes to meet the needs of COVID-19 patients. This session explores how care can be delivered to keep patients safe and how the US will pay for it.
Amy Fahrenkopf, MD, MPH, SVP and General Manager, HSS Health, Hospital for Special Surgery
James Robinson, PhD, MPH, Leonard D. Schaeffer Professor of Health Economics Director, Berkeley Center for Health Technology University of California
Interviewer: Catherine MacLean, MD, PhD, Chief Value Medical Officer, Hospital for Special Surgery